Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CAIX antibody-drug conjugate BAY79-4620

An antibody-drug conjugate (ADC) composed of 3ee9, a monoclonal antibody directed against the tumor-associated antigen (TAA) carbonic anhydrase IX (CAIX; carbonic anhydrase 9; CA9; G250), conjugated via a valine-citrulline (VC) peptide linker to the auristatin derivative and microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of anti-CAIX ADC BAY79-4620, the monoclonal antibody moiety 3ee9 targets and binds to CAIX expressed on tumor cells. Upon internalization, proteolytic cleavage of linker, and the release of MMAE, MMAE targets and binds to tubulin, and inhibits microtubule polymerization. This results in G2/M phase cell cycle arrest and apoptosis in CAIX-expressing tumor cells. CAIX is a member of the carbonic anhydrase family that is found in a majority of renal cell carcinomas while absent in most normal tissues.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:ADC BAY79-4620
anti-CAIX ADC BAY79-4620
anti-CAIX/MMAE ADC BAY79-4620
MN-IC
Code name:BAY 794620
BAY79-4620
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search